155 related articles for article (PubMed ID: 18408224)
1. First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma.
Melichar B; Koralewski P; Ravaud A; Pluzanska A; Bracarda S; Szczylik C; Chevreau C; Filipek M; Delva R; Sevin E; Négrier S; McKendrick J; Santoro A; Pisa P; Escudier B
Ann Oncol; 2008 Aug; 19(8):1470-1476. PubMed ID: 18408224
[TBL] [Abstract][Full Text] [Related]
2. A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN.
Melichar B; Bracarda S; Matveev V; Alekseev B; Ivanov S; Zyryanov A; Janciauskiene R; Fernebro E; Mulders P; Osborne S; Jethwa S; Mickisch G; Gore M; van Moorselaar RJ; Staehler M; Magne N; Bellmunt J;
Ann Oncol; 2013 Sep; 24(9):2396-402. PubMed ID: 23803225
[TBL] [Abstract][Full Text] [Related]
3. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.
Escudier B; Bellmunt J; Négrier S; Bajetta E; Melichar B; Bracarda S; Ravaud A; Golding S; Jethwa S; Sneller V
J Clin Oncol; 2010 May; 28(13):2144-50. PubMed ID: 20368553
[TBL] [Abstract][Full Text] [Related]
4. Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial.
Bracarda S; Bellmunt J; Melichar B; Négrier S; Bajetta E; Ravaud A; Sneller V; Escudier B
BJU Int; 2011 Jan; 107(2):214-9. PubMed ID: 20942831
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab: in first-line treatment of advanced and/or metastatic renal cell carcinoma.
Frampton JE; Keating GM
BioDrugs; 2008; 22(2):113-20. PubMed ID: 18345708
[TBL] [Abstract][Full Text] [Related]
6. FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma.
Summers J; Cohen MH; Keegan P; Pazdur R
Oncologist; 2010; 15(1):104-11. PubMed ID: 20061402
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1.
Donskov F; Jensen NV; Smidt-Hansen T; Brøndum L; Geertsen P
Acta Oncol; 2018 May; 57(5):589-594. PubMed ID: 29392960
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
Rini BI; Bellmunt J; Clancy J; Wang K; Niethammer AG; Hariharan S; Escudier B
J Clin Oncol; 2014 Mar; 32(8):752-9. PubMed ID: 24297945
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
Escudier B; Pluzanska A; Koralewski P; Ravaud A; Bracarda S; Szczylik C; Chevreau C; Filipek M; Melichar B; Bajetta E; Gorbunova V; Bay JO; Bodrogi I; Jagiello-Gruszfeld A; Moore N;
Lancet; 2007 Dec; 370(9605):2103-11. PubMed ID: 18156031
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
Rini BI; Halabi S; Rosenberg JE; Stadler WM; Vaena DA; Archer L; Atkins JN; Picus J; Czaykowski P; Dutcher J; Small EJ
J Clin Oncol; 2010 May; 28(13):2137-43. PubMed ID: 20368558
[TBL] [Abstract][Full Text] [Related]
11. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.
Mickisch G; Gore M; Escudier B; Procopio G; Walzer S; Nuijten M
Br J Cancer; 2010 Jan; 102(1):80-6. PubMed ID: 19920817
[TBL] [Abstract][Full Text] [Related]
12. RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma.
Ravaud A; Barrios CH; Alekseev B; Tay MH; Agarwala SS; Yalcin S; Lin CC; Roman L; Shkolnik M; Anak O; Gogov S; Pelov D; Louveau AL; Melichar B
Ann Oncol; 2015 Jul; 26(7):1378-84. PubMed ID: 25851632
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab in combination with IFN-α in metastatic renal cell carcinoma: the AVOREN trial.
Melichar B; Procházková-Študentová H; Vitásková D
Expert Rev Anticancer Ther; 2012 Oct; 12(10):1253-61. PubMed ID: 23136836
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
Rini BI; Halabi S; Rosenberg JE; Stadler WM; Vaena DA; Ou SS; Archer L; Atkins JN; Picus J; Czaykowski P; Dutcher J; Small EJ
J Clin Oncol; 2008 Nov; 26(33):5422-8. PubMed ID: 18936475
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis.
Ravasio R; Ortega C; Sabbatini R; Porta C
Clin Drug Investig; 2011; 31(7):507-17. PubMed ID: 21627339
[TBL] [Abstract][Full Text] [Related]
16. Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma.
Halabi S; Rini B; Escudier B; Stadler WM; Small EJ
Cancer; 2014 Jan; 120(1):52-60. PubMed ID: 24347384
[TBL] [Abstract][Full Text] [Related]
17. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
May M; Helke C; Bock M; Hoschke B
Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
[TBL] [Abstract][Full Text] [Related]
18. Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).
Donini M; Buti S; Lazzarelli S; Bozzetti R; Rivoltini L; Camisaschi C; Castelli C; Bearz A; Simonelli C; Lo Re G; Mattioli R; Caminiti C; Passalacqua R;
Target Oncol; 2015 Jun; 10(2):277-86. PubMed ID: 25230695
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.
Bukowski RM; Kabbinavar FF; Figlin RA; Flaherty K; Srinivas S; Vaishampayan U; Drabkin HA; Dutcher J; Ryba S; Xia Q; Scappaticci FA; McDermott D
J Clin Oncol; 2007 Oct; 25(29):4536-41. PubMed ID: 17876014
[TBL] [Abstract][Full Text] [Related]
20. Prediction of progression-free survival rates after bevacizumab plus interferon versus interferon alone in patients with metastatic renal cell carcinoma: comparison of a nomogram to the Motzer criteria.
Karakiewicz PI; Sun M; Bellmunt J; Sneller V; Escudier B
Eur Urol; 2011 Jul; 60(1):48-56. PubMed ID: 21190790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
